What is Alluzience?
It’s not every day you see a potential innovation in the world of botulinum toxin!
This is one of a host of new toxins. We have covered Daxxify by Revance - another new toxin whose USP is that it are reported to last approximately six months in duration, rather than the average three of other products. We have also covered Nuceiva, a toxin or “Newtox” made of a similar molecule to Botox itself and Letybo, based on the market leader in Asia. Refer to our Basics of Botox article to get the full summary.
So what is Alluzience?
Alluzience is a brand new botulinum toxin type A (known as liquid abobotulinumtoxinA) first announced in summer 2021 - soon to be launched by Galderma (the company behind Azzalure) in the EU. It represents an exciting innovation with a quicker onset and longer duration than other toxin brands out there. Let’s find out more.
A group of four phase III clinical trials, consisting of approximately 1900 patients, known as the READY clinical programme has since been completed.
Galderma has unveiled Relfydess™ (RelabotulinumtoxinA), the world’s first ready-to-use liquid neuromodulator developed with proprietary PEARL™ Technology. This groundbreaking product has recently received approval for use in Europe. So what is it, and what sets it apart from the other toxins?.